MET and lung cancer: The expression of this axis was also viewed as a prognostic biomarker, representing the clinical response of patients with advanced lung cancer and prostate cancer to c-MET- and vascular endothelial growth factor receptor 2 (VEGFR2)-targeted therapy (92, 118, 129).